UK markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.36+0.86 (+11.47%)
At close: 04:00PM EDT
8.40 +0.04 (+0.48%)
After hours: 04:17PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 394.82M
Enterprise value 536.75M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.89
Price/book (mrq)N/A
Enterprise value/revenue 2.67
Enterprise value/EBITDA -46.10

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 3-46.03%
S&P500 52-week change 3-11.93%
52-week high 317.21
52-week low 34.81
50-day moving average 36.71
200-day moving average 38.62

Share statistics

Avg vol (3-month) 3652.17k
Avg vol (10-day) 3822.04k
Shares outstanding 548.62M
Implied shares outstanding 6N/A
Float 842.27M
% held by insiders 11.84%
% held by institutions 1108.48%
Shares short (14 Jun 2022) 43.28M
Short ratio (14 Jun 2022) 44.84
Short % of float (14 Jun 2022) 46.89%
Short % of shares outstanding (14 Jun 2022) 46.74%
Shares short (prior month 12 May 2022) 45.37M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -34.20%
Operating margin (ttm)-22.78%

Management effectiveness

Return on assets (ttm)-7.55%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)201M
Revenue per share (ttm)4.30
Quarterly revenue growth (yoy)29.90%
Gross profit (ttm)167.29M
EBITDA -13.57M
Net income avi to common (ttm)-68.74M
Diluted EPS (ttm)-1.47
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)195.25M
Total cash per share (mrq)4.02
Total debt (mrq)337.18M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.75
Book value per share (mrq)-2.59

Cash flow statement

Operating cash flow (ttm)-7.19M
Levered free cash flow (ttm)-19.86M